Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

TrivarX Limited

TRI.AXASX
Healthcare
Medical - Healthcare Information Services
$0.03
$0.00(0.00%)
Australian Market opens in NaNh NaNm

TrivarX Limited Fundamental Analysis

TrivarX Limited (TRI.AX) shows weak financial fundamentals with a PE ratio of -14.83, profit margin of 0.00%, and ROE of -7.84%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.15
Current Ratio1.86

Areas of Concern

ROE-7.84%
Operating Margin0.00%
We analyze TRI.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 26.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
26.7/100

We analyze TRI.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

TRI.AX struggles to generate sufficient returns from assets.

ROA > 10%
-7.00%

Valuation Score

Excellent

TRI.AX trades at attractive valuation levels.

PE < 25
-14.83
PEG Ratio < 2
-0.15

Growth Score

Weak

TRI.AX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

TRI.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.01
Current Ratio > 1
1.86

Profitability Score

Weak

TRI.AX struggles to sustain strong margins.

ROE > 15%
-784.24%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is TRI.AX Expensive or Cheap?

P/E Ratio

TRI.AX trades at -14.83 times earnings. This suggests potential undervaluation.

-14.83

PEG Ratio

When adjusting for growth, TRI.AX's PEG of -0.15 indicates potential undervaluation.

-0.15

Price to Book

The market values TrivarX Limited at 1.11 times its book value. This may indicate undervaluation.

1.11

EV/EBITDA

Enterprise value stands at -17.68 times EBITDA. This is generally considered low.

-17.68

How Well Does TRI.AX Make Money?

Net Profit Margin

For every $100 in sales, TrivarX Limited keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-7.84 in profit for every $100 of shareholder equity.

-7.84%

ROA

TrivarX Limited generates $-7.00 in profit for every $100 in assets, demonstrating efficient asset deployment.

-7.00%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

TRI.AX converts -0.59% of its market value into free cash.

-0.59%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-14.83

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.15

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.11

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.01

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.86

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.08

vs 25 benchmark

ROA

Return on assets percentage

-0.07

vs 25 benchmark

ROCE

Return on capital employed

-0.15

vs 25 benchmark

How TRI.AX Stacks Against Its Sector Peers

MetricTRI.AX ValueSector AveragePerformance
P/E Ratio-14.8329.73 Better (Cheaper)
ROE-7.84%777.00% Weak
Net Margin0.00%-23829.00% (disorted) Weak
Debt/Equity0.010.26 Strong (Low Leverage)
Current Ratio1.864.62 Neutral
ROA-7.00%-17661.00% (disorted) Weak

TRI.AX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews TrivarX Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ